Daré Bioscience - DARE Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 1,149.74%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.48
▲ +0.01 (2.13%)

This chart shows the closing price for DARE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Daré Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DARE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DARE

Analyst Price Target is $6.00
▲ +1,149.74% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Daré Bioscience in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 1,149.74% upside from the last price of $0.48.

This chart shows the closing price for DARE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 investment analysts is to moderate buy stock in Daré Bioscience. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
1/30/2024Dawson JamesDowngradeBuy ➝ NeutralLow
11/10/2023HC WainwrightLower TargetBuy ➝ Buy$7.00 ➝ $6.00Low
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$7.00Low
3/31/2023HC WainwrightReiterated RatingBuy$7.00N/A
2/14/2023Brookline Capital ManagementReiterated RatingBuyLow
1/5/2023Roth CapitalInitiated CoverageBuyLow
12/13/2022HC WainwrightBoost TargetBuy$6.00 ➝ $7.00Low
11/30/2022JonestradingInitiated CoverageBuyLow
10/18/2022HC WainwrightReiterated RatingBuy$6.00Low
5/13/2022Maxim GroupInitiated CoverageBuy$4.00High
4/1/2022Maxim GroupInitiated CoverageBuy$4.00High
4/1/2022Roth CapitalBoost Target$11.00 ➝ $17.00High
4/1/2022HC WainwrightBoost TargetBuy$5.00 ➝ $6.00High
1/19/2022Brookline Capital ManagementReiterated RatingBuyHigh
12/8/2021HC WainwrightReiterated RatingBuy$5.00High
7/8/2021HC WainwrightReiterated RatingBuyHigh
6/30/2021Roth CapitalBoost TargetBuy$9.00 ➝ $11.00High
3/31/2021HC WainwrightReiterated RatingBuy$5.00Low
2/15/2021AegisReiterated RatingBuyHigh
12/18/2020HC WainwrightInitiated CoverageBuy$5.00High
12/7/2020Roth CapitalBoost TargetBuy$7.00 ➝ $9.00High
9/10/2020Roth CapitalReiterated RatingBuyHigh
7/12/2020Roth CapitalReiterated RatingBuy$4.00High
7/12/2020AegisReiterated RatingBuy ➝ Market Perform$5.00High
7/12/2020Dawson JamesReiterated RatingBuy$3.00High
6/18/2020Maxim GroupReiterated RatingBuy$3.00Low
6/2/2020AegisReiterated RatingBuyHigh
5/15/2020Maxim GroupInitiated CoverageBuy$3.00Low
4/28/2020Brookline Capital ManagementInitiated CoverageBuy$7.50High
4/1/2020Maxim GroupInitiated CoverageBuy$3.00Low
3/31/2020Roth CapitalLower Target$6.00 ➝ $4.00Medium
3/11/2020Maxim GroupReiterated RatingBuy$3.00High
11/12/2019Maxim GroupReiterated RatingBuy$3.00Medium
9/9/2019Maxim GroupInitiated CoverageBuy$3.00High
8/22/2019AegisInitiated CoverageBuyLow
5/16/2019Maxim GroupReiterated RatingBuy$3.00Low
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/19/2023
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/18/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2023
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/17/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
2/16/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/17/2024
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/16/2024

Current Sentiment

  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Daré Bioscience logo
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy. The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.48
Low: $0.46
High: $0.48

50 Day Range

MA: $0.46
Low: $0.33
High: $0.57

52 Week Range

Now: $0.48
Low: $0.27
High: $1.10

Volume

203,551 shs

Average Volume

259,827 shs

Market Capitalization

$48.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Daré Bioscience?

The following sell-side analysts have issued reports on Daré Bioscience in the last year: Dawson James, and HC Wainwright.
View the latest analyst ratings for DARE.

What is the current price target for Daré Bioscience?

1 Wall Street analysts have set twelve-month price targets for Daré Bioscience in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 1,149.7%. HC Wainwright has the highest price target set, predicting DARE will reach $6.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for Daré Bioscience in the next year.
View the latest price targets for DARE.

What is the current consensus analyst rating for Daré Bioscience?

Daré Bioscience currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DARE.

What other companies compete with Daré Bioscience?

How do I contact Daré Bioscience's investor relations team?

Daré Bioscience's physical mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company's listed phone number is (858) 926-7655 and its investor relations email address is [email protected]. The official website for Daré Bioscience is www.darebioscience.com. Learn More about contacing Daré Bioscience investor relations.